Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.
While the combination of gemcitabine and nab-paclitaxel (Abraxane) has demonstrated survival benefits for patients with metastatic pancreatic cancer, oncologists are interested in knowing whether the regimen will transfer well into the adjuvant setting
$12 million in grants pursued by TGen-George Mason Molecular Medicine Alliance, leveraging institutes' expertise in genomics and proteomics.
Ramesh K. Ramanathan, MD, describes a phase II study that analyzed gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.
Panelists discuss optimism over emerging immunotherapies, novel targets, and enhanced imaging techniques for the treatment of patients with pancreatic cancer.
E. Gabriela Chiorean, MD, discusses the cost-effectiveness of first-line combination therapies commonly used to treat patients with metastatic pancreatic cancer.
In this segment, panelists discuss the recent approval of nab-paclitaxel plus gemcitabine and their selection of a first-line therapy for patients with advanced pancreatic cancer.
Ramesh K. Ramanathan, MD, medical director, Clinical Trials Program, Virginia G. Piper Cancer Center, describes the results from an analysis of metabolic response by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from the phase III MPACT trial.